Auris Medical (EARS) stock: a walking dead or ready to rebound?

5:42 pm ET, 16 Aug 2018

Auris Medical Holding AG (EARS) shares are trading at 0.24, down 1%. What's driving EARS stock price? What's EARS stock price forecast?

Auris Medical is a clinical-stage biotech company developing therapeutics for neurotology and mental health supportive care.  The stock is down 85% since peaking in April at $1.81.  Keep in mind, the company generates a net loss of $3.1 million, and it hasn't produced a penny of revenue yet.  

Here is the progress Auris has made regarding its key development programs (coded AM):

  • The company has requested FDA guidance on AM-111 development program;
  • Top-line data from the second Phase 1 trial for AM-125 for Vertigo is expected in early October;
  • The trial to evaluate the safety, pharmacokinetics and pharmacodynamic effects of AM-201 in co-administration with olanzapine is expected to start in early 2019;
  • The company has two drugs that are in Phase three.

The spike last April was caused by institutional buying; however, a number of short-sellers today is overwhelming. If the company does well next year, when the two Phase three drugs are due, there could be a major price surge.  

What is the sentiment towards the EARS stock? Our technical analysis shows that:

  • The stock short-term sentiment (next 30 days) is negative;
  • The mid-term sentiment (3-6 months) is trending negative;
  • The long-term sentiment (9-12 months) is neutral. 

Over the last month, Auris Medical Holding AG (EARS) returned -5.66%.

Auris Medical Holding AG (EARS) short share of float is 12.11%. The stock is much more frequently shorted than the average industry, sector or S&P 500 stock.

For the latest price and information on Auris Medical Holding AG, please visit Finstead and search for "EARS price" or "EARS news".

Auris Medical Holding AG (EARS) Stock Guide

Updated at: 5:40 pm ET, 17 Sep 2020

Before we start: if you're looking for EARS stock price, you can quickly find it out by visiting Finny and typing "EARS quote". If you're looking for a quick scoop on EARS stock (chart, price target, market cap, news and buy or sell analysis), go to Finny and look for "EARS". You'll get all this info in one place. Or you can just type "EARS news" to get the latest stock news.

Looking to buy or sell Auris Medical Holding AG (EARS)? Interested in getting the full scoop on EARS, including earnings and dividends, stock forecast, buy or sell analysis and key stats? If so, you came to the right place.

In this EARS stock guide, we'll address key questions about EARS, above and beyond what you can find on Yahoo Finance, Zacks, MarketWatch or Morningstar.

Here is what you'll be able to find in this guide:

Earnings and Dividends: earnings, earnings date, dividend rate and dividend yield;
Analyst Predictions: stock forecast and analyst ratings;
Analysis: Finny Score and buy or sell analysis;
Key Stats: revenue, market cap, revenue growth, profit margin, P/E ratio, P/B ratio, industry, sector, and number of employees.

And here is the list of questions we'll answer:
1. What are EARS earnings?
2. What is EARS stock forecast (i.e., prediction)?
3. EARS buy or sell? What is EARS Finny Score?
4. What are the reasons to buy EARS? Why should I buy EARS stock?
5. What are the reasons to sell EARS? Why should I sell EARS stock?
6. What are EARS key stats: revenue, market cap, revenue growth, profit margin, P/E ratio, P/B ratio industry, sector, and number of employees?

So let's start. Scroll down to the question that interests you the most.

Earnings and Dividends

1. What are EARS earnings?

EARS trailing 12-month earnings per share (EPS) is -$1.33.

Analyst Predictions

2. What is EARS stock forecast (i.e., prediction)?

Based on EARS analyst price targets, EARS stock forecast is $14.95 (for a year from now). That means the average analyst price target for EARS stock is $14.95. The prediction is based on 2 analyst estimates.

The low price target for EARS is $14.95, while the high price target is $14.95.

EARS analyst rating is Buy.

Analysis

3. EARS buy or sell? What is EARS Finny Score?

#{finnyScore:null}Our quantitative analysis shows 3 reasons to buy and 0 reasons to sell EARS. EARS doesn’t have an assigned Finny Score, because we don’t have sufficient data points to score the stock.

4. What are the reasons to buy EARS? Why should I buy EARS stock?

Here are the reasons to buy EARS stock:

5. What are the reasons to sell EARS? Why should I sell EARS stock?

We can’t think of any good reason to sell this stock, which doesn’t mean they don’t exist.

Key Stats

6. What are EARS key stats : revenue, market cap, revenue growth, profit margin, P/E ratio, P/B ratio industry, sector, and number of employees?

Let's look at the key statistics for EARS:

Metrics EARS
Price $0.78
Average Price Target / Upside $14.95 / 1,822.34%
Average Analyst Rating Buy
Forward Dividend Yield 0.00%
Industry Biotechnology
Sector Healthcare
Number of Employees 24
Market Cap $5.56M
Forward P/E Ratio -0.20
Price/Book Ratio N/A
Revenue (TTM) N/A
YoY Quarterly Revenue Growth N/A
Profit Margin 0.00%

If you liked this analysis, check out Stock Guides for other stocks.

Follow Us